ALZN
Price
$1.29
Change
+$0.03 (+2.38%)
Updated
Oct 16, 10:53 AM (EDT)
Capitalization
8.35M
75 days until earnings call
Intraday BUY SELL Signals
VRAX
Price
$1.58
Change
-$0.04 (-2.47%)
Updated
Oct 16, 11:07 AM (EDT)
Capitalization
1.84M
Intraday BUY SELL Signals
Interact to see
Advertisement

ALZN vs VRAX

ALZN vs VRAX Comparison Chart in %
loading
loading
View a ticker or compare two or three
VS
ALZN vs. VRAX commentary
Oct 16, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is ALZN is a Hold and VRAX is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for ALZN with price predictions
Oct 15, 2026

ALZN in downward trend: price dove below 50-day moving average on October 01, 2026

ALZN moved below its 50-day moving average on October 01, 2026 date and that indicates a change from an upward trend to a downward trend. In 35 of 38 similar past instances, the stock price decreased further within the following month. The odds of a continued downward trend are 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on September 30, 2026. You may want to consider selling the stock, shorting the stock, or exploring put options on ALZN as a result. In 70 of 80 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are 88%.

The Moving Average Convergence Divergence Histogram (MACD) for ALZN turned negative on September 25, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 37 similar instances when the indicator turned negative. In 33 of the 37 cases the stock turned lower in the days that followed. This puts the odds of success at 89%.

The 10-day moving average for ALZN crossed bearishly below the 50-day moving average on October 07, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 10 of 11 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALZN declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ALZN's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

The 50-day moving average for ALZN moved above the 200-day moving average on September 28, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.

Following a +6.02% 3-day Advance, the price is estimated to grow further. Considering data from situations where ALZN advanced for three days, in 170 of 210 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

ALZN may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

The Aroon Indicator entered an Uptrend today. In 76 of 82 cases where ALZN Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 90%.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 17 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.439) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (0.000) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 61 (best 1 - 100 worst), indicating steady price growth. ALZN’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 99 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ALZN’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for VRAX with price predictions
Oct 15, 2026

Momentum Indicator for VRAX turns negative, indicating new downward trend

VRAX saw its Momentum Indicator move below the 0 level on October 06, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 74 similar instances where the indicator turned negative. In 71 of the 74 cases, the stock moved further down in the following days. The odds of a decline are at 90%.

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Moving Average Convergence Divergence Histogram (MACD) for VRAX turned negative on October 06, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 35 similar instances when the indicator turned negative. In 33 of the 35 cases the stock turned lower in the days that followed. This puts the odds of success at 90%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where VRAX declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 90%.

The Aroon Indicator for VRAX entered a downward trend on October 02, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator demonstrates that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 11 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.

Following a +7.66% 3-day Advance, the price is estimated to grow further. Considering data from situations where VRAX advanced for three days, in 137 of 169 cases, the price rose further within the following month. The odds of a continued upward trend are 81%.

VRAX may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 23 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.243) is normal, around the industry mean (26.782). P/E Ratio (0.000) is within average values for comparable stocks, (43.395). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (79.365) is also within normal values, averaging (437.542).

The Tickeron Price Growth Rating for this company is 94 (best 1 - 100 worst), indicating slightly worse than average price growth. VRAX’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 100 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VRAX’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

TECHNICAL ANALYSIS
Technical Analysis
ALZNVRAX
RSI
ODDS (%)
Bullish Trend 1 day ago
86%
Bullish Trend 1 day ago
84%
Stochastic
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
88%
Momentum
ODDS (%)
Bearish Trend 1 day ago
88%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bearish Trend 1 day ago
89%
Bearish Trend 1 day ago
90%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
81%
Bullish Trend 24 days ago
81%
Declines
ODDS (%)
Bearish Trend 16 days ago
90%
Bearish Trend 1 day ago
90%
BollingerBands
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
90%
Aroon
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
90%
COMPARISON
Comparison
Oct 16, 2026
Stock price -- (ALZN: $1.26 vs. VRAX: $1.62)
Brand notoriety: ALZN and VRAX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: ALZN: 12% vs. VRAX: 18%
Market capitalization -- ALZN: $8.35M vs. VRAX: $1.84M
ALZN [@Biotechnology] is valued at $8.35M. VRAX’s [@Biotechnology] market capitalization is $1.84M. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $133.74B. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

ALZN’s FA Score shows that 1 FA rating(s) are green while VRAX’s FA Score has 1 green FA rating(s).

  • ALZN’s FA Score: 1 green, 4 red.
  • VRAX’s FA Score: 1 green, 4 red.
According to our system of comparison, ALZN is a better buy in the long-term than VRAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

ALZN’s TA Score shows that 6 TA indicator(s) are bullish while VRAX’s TA Score has 4 bullish TA indicator(s).

  • ALZN’s TA Score: 6 bullish, 5 bearish.
  • VRAX’s TA Score: 4 bullish, 4 bearish.
According to our system of comparison, ALZN is a better buy in the short-term than VRAX.

Price Growth

ALZN (@Biotechnology) experienced а -5.97% price change this week, while VRAX (@Biotechnology) price change was -18.59% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -7.32%. For the same industry, the average monthly price growth was -15.10%, and the average quarterly price growth was -18.48%.

Reported Earning Dates

ALZN is expected to report earnings on Dec 30, 2026.

Industries' Descriptions

@Biotechnology (-7.32% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

View a ticker or compare two or three
ALZN
Daily Signal:
Gain/Loss:
VRAX
Daily Signal:
Gain/Loss:
Interact to see
Advertisement
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NMRA0.430.07
+20.45%
Neumora Therapeutics
MSBI32.300.46
+1.44%
Midland States Bancorp
RVSN2.930.01
+0.34%
Rail Vision Ltd
SQM60.47-1.17
-1.90%
Sociedad Quimica y Minera de Chile SA
CXW31.23-1.33
-4.08%
CoreCivic

ALZN and

Correlation & Price change

A.I.dvisor indicates that over the last year, ALZN has been loosely correlated with VRAX. These tickers have moved in lockstep 46% of the time. This A.I.-generated data suggests there is some statistical probability that if ALZN jumps, then VRAX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ALZN
1D Price
Change %
ALZN100%
-6.67%
VRAX - ALZN
46%
Loosely correlated
-1.82%
FTH - ALZN
41%
Loosely correlated
+3.00%
LTRN - ALZN
39%
Loosely correlated
-0.92%
ASBP - ALZN
38%
Loosely correlated
+6.62%
SILO - ALZN
33%
Loosely correlated
N/A
More

VRAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRAX has been loosely correlated with ALZN. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if VRAX jumps, then ALZN could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRAX
1D Price
Change %
VRAX100%
-1.82%
ALZN - VRAX
45%
Loosely correlated
-6.67%
NTRB - VRAX
31%
Poorly correlated
-0.79%
PTGX - VRAX
30%
Poorly correlated
+0.20%
CAPR - VRAX
30%
Poorly correlated
+10.32%
DYAI - VRAX
29%
Poorly correlated
+1.55%
More